Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Does IBC publishs the scandium results tomorrow?
Nice timing CUIN2
More time, more money at lower sp, more sceptic, ...
Best stock loooooool
I would expect, that theralase anounces a new pp at 0,1 CAD, looool
Landmark,
which questions will calm you / us down?
I mean, if financing is not signed -> No information will be given in Q&A
If a scandium offtake is not signed -> No information will be given in Q&A
Strategie to support shareprice? -> Staring world wide investors campaign
I dont see any question which will calm us down, which they are allowed to answer in the detail we will need to feel save.
My opinion -> At christmas we see a SP of 0,20 to 0,25 Us$
(No information from management, tax loss selling, overall market at alltime high, ...)
Thats my time, when i'll be back :D
Please correct me if I'm wrong.
I agree
I agree, but Mark also said, that the debt wont commit until the equity commits and vice versa.
The debt side sees the shareprice as well and might be wondering, if it is a good idea, to lend maybe 200m $, if the shareprice is that low and will cause a big dilution. So they might hold back until the equity side commits to a much higher sp for first equity package.
I guess that deadlock wont simplify, when the prices drops even more.
Still no information from ibc regarding scandium alloy tests
I offer a scandium offtake for the complete 100 metric tons for 1€ per ton.
This is my official offer.
ColdDarkHole,
you are always welcome to buy a big chunk of cheap shares.
But I'm not sure if they are cheap at the moment.
We are told this since a long long time. So probably they will be cheaper tomorrow ;)
But this is only my humble opinion
image
Theralase Anti-Cancer Drugs Independently Reviewed
Toronto, Ontario – October 31, 2017, Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a leading biotech company focused on the commercialization of medical lasers to eliminate pain and the development of Photo Dynamic Compounds (“PDCs”) to destroy cancer, announced today that a recent peer-reviewed paper entitled, “Novel Osmium-based Coordination Complexes as Photosensitizers for Panchromatic Photodynamic Therapy”, presenting research on Theralase licensed Osmium PDCs, has been independently reviewed by Dr. Edith C. Glazer in her recent paper entitled, “Panchromatic Osmium Complexes for Photodynamic Therapy: Solutions to Existing Problems and New Questions”.
Edith C. Glazer, Ph.D., Associate Professor, Department of Biological Chemistry, University of Kentucky, Lexington, Kentucky provided an independent review of “Novel Osmium-based Coordination Complexes as Photosensitizers for Panchromatic Photodynamic Therapy” where she states that, “The validation of Osmium coordination complexes as photosensitizers for PDT, with very promising in vivo results, demonstrate radical improvements in survival following irradiation with visible (635 nm) or Near InfraRed (“NIR”) (808 nm) light. An unusual feature in the study is that the different complexes exhibit disparate photophysical and photobiological characteristics, despite sharing common structural motifs. These findings raise hopes for the development of novel photosensitizers that overcome the limitations of current commercially available systems for PDT, but also raise questions regarding the most efficacious biological Mechanisms Of Action (“MOA”) for this treatment modality.”
Dr. Glazer’s abstract and complete article is available at:
http://onlinelibrary.wiley.com/doi/10.1111/php.12796/abstract
The abstract and complete original article are available at:
https://doi.org/10.1111/php.12767
The original article describes how, “Cancer remains a major global malaise requiring the advent of new, efficient and low-cost treatments. PDT, which combines a photosensitizer and photons to produce cytotoxic reactive oxygen species, has been established as an effective cancer treatment, but has yet to become mainstream. One of the main limitations has been the paucity of photosensitizers that are effective over a wide range of wavelengths, can exert their cytotoxic effects in hypoxia (low oxygen), are easily synthesized and produce few if any side effects. To address these shortfalls, three new Osmium-based photosensitizers (TLD-1822, TLD-1824 and TLD-1829) were synthesized and their photophysical and photobiological attributes determined. These photosensitizers are panchromatic (i.e.: black absorbers), activatable from 200 to 900 nm and have strong resistance to photobleaching (ability to be light activated for longer periods of time without losing efficacy). In vitro studies show PDT efficacy with both red and NIR light in normoxic (normal oxygen) and hypoxic conditions, which translated to good in vivo efficacy of TLD-1829 in a subcutaneous mouse colon cancer model.
Sherri McFarland, Ph.D., Professor, Department of Chemistry and Biochemistry, University of North Carolina at Greensboro, the original inventor of the Osmium based PDCs, stated that, “I am delighted that our work with Osmium-based PDCs is being recognized by leaders in the field of light-responsive metallodrugs. Dr. Glazer wrote a very supportive highlight of our work in the specialized journal Photochemistry and Photobiology (2017, 93, 1326-1328), where she iterated the promise of these new PDCs as PDT agents and commended us on our efficacy-based, multidisciplinary collaborative approach to drug discovery. She notes that ‘one of the greatest implications of our work is that it serves as an example of the remarkable progress that can be made when academic and industrial groups tackle an underexplored area’. I look forward to continuing a productive collaboration with medical biophysicist Dr. Lothar Lilge and the entire Theralase team.”
Arkady Mandel, MD, Ph.D., D.Sc., Chief Scientific Officer of Theralase stated that, “The latest research and subsequent independent review of the Theralase licensed Osmium PDCs demonstrate the growing interest in this field of cancer research and the attention that Theralase’s research is starting to generate in the international research community. I look forward to continuing our research in this field with Dr. McFarland and Dr. Lilge, and the expansion of our clinical applications using these cutting-edge PDCs.”
Roger Dumoulin-White, President and CEO of Theralase stated that, “Theralase is committed to expanding our Phase Ib clinical research program to include new oncological targets, using both our Ruthenium (TLD-1433) and Osmium ((TLD-1822, TLD-1824 and TLD-1829) based PDCs. We look forward to presenting this research to the international scientific and medical communities.”
About Theralase Technologies Inc.
Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF) in its Therapeutic Laser Technology (“TLT”) Division designs, manufactures, markets and distributes patented super-pulsed laser technology indicated for the treatment of chronic knee pain, and in off-label use, the elimination of pain, reduction of inflammation and dramatic acceleration of tissue healing for numerous nerve, muscle and joint conditions. Theralase’s Photo Dynamic Therapy (“PDT”) Division researches and develops specially designed molecules called Photo Dynamic Compounds (“PDCs”), which have demonstrated an ability to localize to cancer cells and then when laser light activated, effectively destroy them.
Additional information is available at www.theralase.com and www.sedar.com .
This news release contains "forward-looking statements" which reflect the current expectations of management of the Corporation’s future growth, results of operations, performance and business prospects and opportunities. Such statements include, but are not limited to, statements regarding the proposed use of proceeds. Wherever possible, words such as "may", "would", "could", “should”, "will", "anticipate", "believe", "plan", "expect", "intend", "estimate", "potential for" and similar expressions have been used to identify these forward-looking statements. These statements reflect management's current beliefs with respect to future events and are based on information currently available to management. Forward-looking statements involve significant risks, uncertainties and assumptions. Many factors could cause the Corporation’s actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements; including, without limitation, those listed in the filings made by the Corporation with the Canadian securities regulatory authorities (which may be viewed at www.sedar.com). Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward looking statements prove incorrect, actual results, performance or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in the news release are based upon what management currently believes to be reasonable assumptions, the Corporation cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements. The Corporation disclaims any intention or obligation to revise forward-looking statements whether as a result of new information, future developments or otherwise except as required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.
For More Information:
Roger Dumoulin-White
President & CEO
1.866.THE.LASE (843-5273) ext. 225
416.699.LASE (5273) ext. 225
rwhite@theralase.com
www.theralase.com
Unsubscribe
Theralase Inc. 1945 Queen Street East Toronto, Ontario M4L 1H7 Canada
You have to ask walterc, he is big into this :D
Hi Photonics,
may you please give a short overview of the timeline for financing + build + production?
Thanks
You are raising expectations
This must be a joke.
30 days and we will have the final permit needed to start financing / production, and it seems we close in red today.
this stock is going ballistic, lol
Is this an official advice to buy niocorp?
No qeustion about that, but still to wait till the bottom, if there is any.
LIke me, who is laughing his ass off :D
Why do you predict them to be released next week?
Lool, you got your update today.
Next mail in 2 weeks and downtrend continues.
But that is just my opinion on my 25 shares.
Let him sell his 25 shares. :D lol
Didn't they say that production will start 2018 / 2019?
With the 4 years timeline, it will start 2022. loool
Hope we will meet 2025 as deadline for our mine
Why should somebody start an international marketing compain, if financing is already alined with big banks? Why spend several millions, if its not needed? They will need money sooner than later and have to give out new shares in a new pp at this or a lower level.
I am just a small retailer with no knowledge in this sector, but their strategie doenst make any sense for me.
Soinds like they will just start to get in contact with some investors to secure financing. That will take a long time again. At these level, they dont have much time. I guess if they dont secure financing till years end, it will be even worse.
Thought they are already some steps further.
They dont need to attract some small pocket retail investors. They wont help to rise the pps as much as niocorp need it at the moment. But that is one point, why i have sold 3/4 of my holding so far.
Just my opinion.
Theralase Lead Anti-Cancer Drug Effective in the Destruction of Brain Cancer when Activated by X-Rays
Toronto, Ontario (FSCwire) - Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a leading biotech company focused on the commercialization of medical lasers to eliminate pain and the development of Photo Dynamic Compounds (“PDCs”) to destroy cancer, announced today that its patented, lead anti-cancer drug, TLD-1433, when activated by X-rays, has been demonstrated preclinically, to be effective in the destruction of human GlioBlastoma Multiforme (“GBM”) cancer cells, a deadly form of brain cancer.
According to the American Brain Tumor Association:
“GBM are tumors that arise from astrocytes—the star-shaped cells that make up the “glue-like,” or supportive tissue of the brain. These tumors are usually highly malignant (cancerous) because the cells reproduce quickly, being supported by a large network of blood vessels.”
“Nearly 80,000 new cases of primary brain tumors are expected to be diagnosed in the US this year, with approximately 32% of brain and central nervous system tumors presenting as malignant.”
“GBM represents 14.9% of all primary brain tumors and 55.4% of all gliomas. GBM has the highest number of cases of all malignant tumors, with an estimated 12,390 new cases predicted in 2017.”
“For adults with more aggressive GBM, treated with concurrent temozolamide (oral chemotherapy drug) and radiation therapy, median survival is about 14.6 months and two-year survival is 30%.”
“The first step in treating GBM is a procedure to make a diagnosis, relieve pressure on the brain, and safely remove as much tumor as possible through surgery. Because GBMs have finger-like tentacles, they are very difficult to completely remove. This is particularly true when they are growing near the parts of the brain that control important functions such as language and coordination. Radiation and chemotherapy may be used to slow the growth of tumors that cannot be removed with surgery. Chemotherapy may also be used to delay the need for radiation in young children.”
Theralase’s preclinical research is focused on determining whether its feasible that Rutherrin® (TLD-1433 + transferrin) injected IntraVenously (“IV”) into a patient diagnosed with GBM is able to fulfill the 4 criteria below:
Effectively cross the blood brain barrier and localize preferentially to GBM tumors
Once absorbed by the GBM tumors, safely and effectively destroy them, when activated by X-rays transcranially through the skull
Remove the need for surgical debridement
Complete the destruction of the GBM tumors at or below current standard of care radiation levels
In research conducted by Pavel Kaspler, Ph.D., Research Scientist and Manunatha Munegowda, Ph.D., Research Scientist, both of Theralase, under the direction of Arkady Mandel, MD, Ph.D., D.Sc., Chief Scientific Officer, Theralase, Rutherrin® has been demonstrated to possess the ability to selectively uptake into malignant GBM tumor cells (demonstrated in a rat RG2 cell-induced brain tumor model) over 22 times greater than in normal brain tissue, fulfilling criteria 1 above. (see Figure 1)
Figure 1. Rutherrin® uptake into RG2 cell-induced GBM tumor is highly selective, as verified by Inductively Coupled Plasma - Mass Spectrometry analysis 4 hours post Rutherrin® injection. (To view the graphic in its original size, please click here)
The GMB selectivity is believed to be due to the much higher expression of Transferrin Receptors (“TfR”) in brain tumors versus normal brain cells (approximately 10 times) (see Figures 2 to 4).
Figure 2. Expression of TfR is much higher in GBM than in normal brain tissue. (To view the graphic in its original size, please click here)
Figure 3. Cells positive for TfRs are more common in RG2 brain tumor than in normal tissue. Left panels show TfR immuno staining. Intensity of brown color of immuno staining indicates the intensity of TfR expression. Right panels show Hematoxylin and Eosin (“H&E”) staining again demonstrating greater TfR density in GBM tumor versus normal tissue. (To view the graphic in its original size, please click here)
Figure 4. Brain TfRs are predominantly localized in RG2 cells-induced GBM tumor (Left panel, dark brown staining). Neither healthy brain tissue outside of the tumor (Left panel) nor brain without tumor (Right panel) showed intense TfR staining. (To view the left graphic in its original size, please click here) (To view the right graphic in its original size, please click here)
TLD-1433 at a low dose (80 micromolar) has demonstrated an ability to be activated by X-ray (20 Gy, 225 keV) in human GBM (U87) cancer cells. At these X-ray radiation levels, GBM cell kill was approximately 75% versus negligible GBM cell kill with X-ray radiation alone, suggesting that cell kill was exclusively the result of TLD-1433 X-ray activation, fulfilling criteria 2 above.
Figure 5. High cell kill in GBM cells (U87) (measured by Presto Blue assay) by X-ray activated TLD-1433 versus negligible cell kill by X-ray alone. (To view the graphic in its original size, please click here)
Dr. Kaspler stated that, “This latest research data strongly supports that TLD-1433 would be effective in the destruction of human GBM cancer cells with a high safety margin. It is noteworthy that a high GBM cell kill by X-ray activated TLD-1433 was achieved at quantum energy levels significantly below that used clinically to treat GBM (225 keV versus 6 MeV, a 27 fold difference), suggesting a greater safety profile to healthy brain tissue during X-ray tumor treatment, fulfilling criteria 4 above.”
Dr. Mandel stated that, “TLD-1433 continues to advance preclinically and clinically in the destruction of new oncology targets. TLD-1433 GBM cell kill was observed at X-ray dosages of 20 Gy, that did not induce appreciable cell kill, without the presence of TLD-1433. This helps to confirm the phenomenon of radio-resistance of malignant GBM and suggests that this radio-resistance can be overcome by the X-ray irradiation of GBM tumor cells in the presence of TLD-1433. Given the potential benefit to improve tumor control, patient quality of life and survival, by combining an established method of radiation therapy, with an advanced radiation enhancer (TLD-1433), which modifies the tumor to become more sensitive to radiation therapy, is of high clinical interest and significance. The pre-clinical studies, completed to date, have shown antitumor synergy when TLD-1433 is combined with radiation therapy. This data conjointly, with a well-established manufacturing process for TLD-1433, and the strong safety profile observed in TLD-1433 treated patients in the on-going Phase Ib clinical study for Non-Muscle Invasive Bladder Cancer, looks even more exciting and calls for additional vigorous investigations into further experiments, which if successful, will lead to the design and commencement of a Phase Ib GBM clinical study.”
Roger Dumoulin-White, President and CEO of Theralase stated that, “This latest research confirms that the Company is on the right track to provide support for the design and commencement of a Phase Ib clinical study for patients inflicted with this deadly disease. Theralase will continue its research to identify if surgical debridement can be eliminated, fulfilling criteria 3 above. If a patient is able to receive an IV injection of Rutherrin® and then a specified number of hours later, after the PDC has been selectively absorbed into their GBM cancer cells versus normal brain cells, to receive X-ray activation transcranially, at levels at or below standard of care, providing for the safe and effective destruction of their GBM cancer, with minimum side effects, then this would be well worth the time and effort the Company has invested into this cutting-edge research.”
Will buy back my shares around january next year. lets see who is right.
It wont happen. They mentioned some uplisting possibility around 1,5 years back. Nothing happend.
As I already said some month ago, results for the 6 patients will be availabe earliest in Q1 2018, more likely to be in Q2 2018. this will be the time where it starts to rise. I guess and thats just my opinion. Not much will happen.
Theralase Lead Anti-Cancer Drug Effective in the Destruction of Throat Cancer
Toronto, Ontario (FSCwire) - Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a leading biotech company focused on the commercialization of medical lasers to eliminate pain and the development of Photo Dynamic Compounds (“PDCs”) to destroy cancer, announced today that its patented, lead anti-cancer drug, TLD-1433, has been proven effective in the destruction of a human pharyngeal carcinoma cell line, FaDu.
In 2016, according to the American Society of Clinical Oncology (“ASCO”), an estimated 49,670 adults (35,720 men and 13,950 women) in the United States will be diagnosed with oral and oropharyngeal cancer. Rates of these cancers are more than twice as high in men, as in women. Cancer of the oral cavity is the ninth most common cancer among men. The average age of diagnosis is 62.
The overall 5-year survival rate for people with oral or oropharyngeal cancer is 64%.
It is estimated that 9,700 deaths (7,000 men and 2,700 women) from these 2 diseases will occur this year.
In research conducted by Pavel Kaspler, Ph.D., Research Scientist, Theralase, under the direction of Arkady Mandel, MD, Ph.D., D.Sc., Chief Scientific Officer, Theralase, it has been demonstrated that a human pharyngeal carcinoma cell line (FaDu) was 98% destroyed, at an extremely low dose of TLD-1433 (0.2 micromolar), when activated by green laser light (530 nm, 90 J/cm2) and 98% destroyed, at a low dose of TLD-1433 (25 micromolar), when activated by red laser light (625 nm, 90 J/cm2).
The ability to activate TLD-1433 at both green and red laser wavelengths allows the PDC to be activated at various tissue depths corresponding to the progression of the disease.
The dark toxicity (TLD-1433, but no laser light applied) was virtually negligible, when activated by green laser light, and low, when activated by red laser light, supporting a high safety margin in the destruction of human pharyngeal carcinoma cells.
Dr. Kaspler stated that, “The research data strongly supports that TLD-1433 would be effective in the destruction of human pharyngeal carcinoma cells with a high safety margin. I look forward to continuing my research in this promising new cancer indication.”
Dr. Mandel stated that, “TLD-1433 continues to advance in the destruction of new oncology targets, demonstrating high efficacy in the destruction of numerous cancers preclinically. We have strong preclinical data supporting the use of Rutherrin® (TLD-1433 + transferrin) in the destruction of glioblastoma brain cancer and lung cancer and now TLD-1433 on its own in the destruction of cervical and pharyngeal cancer.”
Roger Dumoulin-White, President and CEO of Theralase stated that, “The Theralase licenced PDCs have proven to be very strong anti-cancer drugs in initial clinical studies for NMIBC and preclinically for glioblastoma, lung, cervical and now pharyngeal cancer. We look forward to successfully expanding the clinical application of our platform of PDCs, and the laser light systems that activate them, through Phase Ib clinical studies, as we expand into these new oncological targets.”
Looool, good luck
Hi AO, I agree.
I think its not the right investment for my any longer, to much disappointment and anger.
I dont see the hugh return of this invest. There are much better investment out there. As I said I will just sell 2/4 of my 3/4, but I wont follow this story any longer.
For my peace of mind I need a more promising base of investment and that doesn't mean a blue chip, but again a startup.
I stop to annoy you all any longer, last post.
:D sorry Jim, but your reply just show how much you regret your investment in nio and how disappointed you really are.
I felt in love with nio for to long now. Invested over 5 -6 years and lost trust in management for over a year. Its time for me follow the advice of so many investors here, to sell and go. I regret, that I didnt do it early.
I wish you all the best.
Putz you are right, it means before year end 2018
Only because the newspaper is owned by Berkshire, you indicate, that they could be willing to invest in niocorp? How many companies are mentioned in that newspaper every week?
There are other indications than just mentioning in a newspaper.
Some days I read, that Berkshire's cash basis is really high at the moment, because Buffett thinks that the market is already too expensive to invest in.
At the end of Q2 2017, Berkshire has a cash basis of around 100 billion $.
One year ago, they just had 70 billion $.
If the normal market it too expensive, maybe he is searching for investment, which are just about to start.
I guess this is a better indication that just been mentioned in a newspaper.
http://www.manager-magazin.de/finanzen/boerse/warren-buffett-100-milliarden-cash-sind-fuer-berkshire-ein-problem-a-1161832.html
That mean?
Aha, lol
You can use this page to get info about a hold immediately:
http://www.finanznachrichten.de/nachrichten-aktien/excelsior-mining-corp.htm
no, it was holded yesterday.
Why do You think it has been holded?